Compare Quantum Computing Inc (QUBT) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quantum Computing Inc vs Zimmer Biomet Holdings Inc — how do they compare? Quantum Computing Inc trades at $7.44 (market cap $1.69B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 10× Quantum Computing Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Quantum Computing Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quantum Computing Inc for 25 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| QUBT | ZBH | |
|---|---|---|
Market Cap | $1.69B | $16.95B |
Volume | 7,991,522 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $21.78 | $103.98 |
52-Week Low | $6.31 | $79.58 |
Typical Hold Time | 25 Days | 89 Days |
Enterprise Value | $753.24M | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quantum Computing Inc. (QUBT) trades at $7.44, down 2.36% on the day, with a bearish technical signal despite bullish oscillators. The company shows explosive revenue growth from $682K in 2025 to $10M projected for 2026, but remains deeply unprofitable with a -152.45% net income margin. Recent developments include the Dirac-3S quantum system launch and a $42.5M backlog, though rising expenses and shareholder litigation pose challenges.
QUBT offers significant upside potential with a consensus price target of $17.33 (133% upside) and 75% analyst buy ratings, supported by strong revenue growth and technological advancements. However, the stock carries high risk due to persistent losses, negative cash flow from operations, and execution challenges in the competitive quantum computing space.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
